Genetic Predisposition Syndromes and Their Management

Surgical Clinics of North America

Volumn 93, Issue 2, 2013, Pages 341-362

  Euhus, David M ^a,b   Robinson, Linda ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Breast neoplasms; Cancer predisposition syndromes; Gene mutation; Genetic counseling; Risk assessment; Risk management

Indexed keywords

CISPLATIN; DOCETAXEL; OLAPARIB; PACLITAXEL; TAMOXIFEN;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RISK; CHEMOPROPHYLAXIS; DRUG MECHANISM; FAMILIAL CANCER; GENE MUTATION; GENETIC COUNSELING; GENETIC DISORDER; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC SCREENING; GENETIC VARIABILITY; HETEROZYGOTE; HUMAN; INTERMETHOD COMPARISON; MASTECTOMY; ONCOGENE; OVARY CANCER; PARTIAL MASTECTOMY; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SALPINGOOOPHORECTOMY; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84875287730     PISSN: 00396109     EISSN: 15583171     Source Type: Journal    
DOI: 10.1016/j.suc.2013.01.005     Document Type: Review

References (138)

1. Lebert H. Traite pratique des maladies cancereuses 1851, Librarie de L'Academie Nationale de Medecine, Paris, p. 134-5.
2. Mendel G. Versuche über Pflanzenhybriden Verh. Naturforscher-Verein Brünn 1865, 4:3-47.
3. Miescher F. Ueber die chemische Zusammensetzung der Eiterzellen. Medicinisch-Chemische Untersuchungen 1871, 4:441-460.
4. Avery O.T., MacLeod C.M., McCarty M. Studies on the chemical nature of the substance inducing transformation of pneumococcal types: induction of transformation by a desoxyribonucleic acid fraction isolated from pneumococcus type III. J Exp Med 1944, 79:137-158.
5. Solomon E., Ledbetter D.H. Report of the Committee on the Genetic Constitution of Chromosome 17. Cytogenet Cell Genet 1991, 58:686-738.
6. Hall J.M., Lee M.K., Newman B., et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990, 250:1684-1690.
7. Broca P. Traite des tumeurs 1866, Asselin, Paris, p. 150-2.
8. Malkin D., Li F.P., Strong L.C., et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990, 250:1233-1238.
9. Miki Y., Swensen J., Shattuck-Eidens D., et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994, 266(5182):66-71.
10. Wooster R., Neuhausen S.L., Mangion J., et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994, 265(5181):2088-2090.
11. Wooster R., Bignell G., Lancaster J., et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995, 378:789-792.
12. Tavtigian S.V., Simard J., Rommens J., et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet 1996, 12:333-337.
13. D'Andrea A.D., Grompe M. The Fanconi anemia/BRCA pathway. Nat Rev Cancer 2003, 3:23-34.
14. Casadei S., Norquist B.M., Walsh T., et al. Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. Cancer Res 2011, 71:2222-2229.
15. Jacquemont C., Taniguchi T. Disruption of the Fanconi anemia pathway in human cancer in the general population. Cancer Biol Ther 2006, 5:1637-1639.
16. Heikkinen K., Rapakko K., Karppinen S.M., et al. RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability. Carcinogenesis 2006, 27:1593-1599.
17. De Nicolo A., Tancredi M., Lombardi G., et al. A novel breast cancer-associated BRIP1 (FANCJ/BACH1) germ-line mutation impairs protein stability and function. Clin Cancer Res 2008, 14:4672-4680.
18. Bell D.W., Varley J.M., Szydlo T.E., et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 1999, 286:2528-2531.
19. Borg å., Sandberg T., Nilsson K., et al. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst 2000, 92:1260-1266.
20. de Snoo F.A., Bishop D.T., Bergman W., et al. Increased risk of cancer other than melanoma in CDKN2A founder mutation (p16-Leiden)-positive melanoma families. Clin Cancer Res 2008, 14:7151-7157.
21. Mester J., Eng C. Estimate of de novo mutation frequency in probands with PTEN hamartoma tumor syndrome. Genet Med 2012, 14(9):819-822.
22. Marsh D.J., Coulon V., Lunetta K.L., et al. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet 1998, 7:507-515.
23. Fitzgerald R.C., Hardwick R., Huntsman D., et al. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet 2010, 47:436-444.
24. Schrader K.A., Masciari S., Boyd N., et al. Hereditary diffuse gastric cancer: association with lobular breast cancer. Fam Cancer 2008, 7:73-82.
25. Hearle N., Schumacher V., Menko F.H., et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res 2006, 12:3209-3215.
26. Antoniou A.C., Pharoah P.D., McMullan G., et al. A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer 2002, 86:76-83.
27. Janavicius R. Founder BRCA1/2 mutations in Europe: implications for hereditary breast-ovarian cancer prevention and control. EPMA J 2010, 1:397-412.
28. Offit K., Pierce H., Kirchhoff T., et al. Frequency of CHEK2*1100delC in New York breast cancer cases and controls. BMC Med Genet 2003, 4:1-4.
29. Vahteristo P., Bartkova J., Eerola H., et al. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet 2002, 71:432-438.
30. Easton D.F., Pooley K.A., Dunning A.M., et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007, 447:1087-1093.
31. Pharoah P.D., Antoniou A.C., Easton D.F., et al. Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med 2008, 358:2796-2803.
32. Antoniou A.C., Beesley J., McGuffog L., et al. Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res 2010, 70:9742-9754.
33. Mulligan A.M., Couch F.J., Barrowdale D., et al. Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res 2011, 13:R110.
34. Eggington JM, Burbridge LA, Roa B, et al. Current variant of uncertain significance rates in BRCA1/2 and Lynch syndrome testing (MLH1, MSH2, MSH6, PMS2, EpCam). American College of Medical Genetics Annual Clinical Genetics Meeting. Charlotte, March 27-31, 2012.
35. Frank T.S., Deffenbaugh A.M., Reid J.E., et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 2002, 20:1480-1490.
36. Easton D.F., Deffenbaugh A.M., Pruss D., et al. A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am J Hum Genet 2007, 81:873-883.
37. Nanda R., Schumm L.P., Cummings S., et al. Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. JAMA 2005, 294:1925-1933.
38. Weitzel J.N., Lagos V., Blazer K.R., et al. Prevalence of BRCA mutations and founder effect in high-risk Hispanic families. Cancer Epidemiol Biomarkers Prev 2005, 14:1666-1671.
39. Finkelman B.S., Rubinstein W.S., Friedman S., et al. Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers. J Clin Oncol 2012, 30:1321-1328.
40. Judkins T., Rosenthal E., Arnell C., et al. Clinical significance of large rearrangements in BRCA1 and BRCA2. Cancer 2012, 118(21):5210-5216.
41. Riley B.D., Culver J.O., Skrzynia C., et al. Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors. J Genet Couns 2012, 21:151-161.
42. National Comprehensive Cancer Network. Genetic/familial high-risk assessment: breast and ovarian, NCCN Clinical Practice Guidelines in Oncology v.1.2012. Fort Washington (PA): 2012. Available at:. Accessed February 1, 2013. http://www.nccn.org/professionals/physician_gls/PDF/genetics_screening.pdf.
43. Berry D.A., Parmigiani G., Sanchez S., et al. Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst 1997, 89:227-238.
44. Tyrer J., Duffy S.W., Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 2004, 23:1111-1130. [Erratum appears in Stat Med 2005;24(1):156].
45. Euhus DM. Cancer Gene 2012. Available at:. Accessed February 1, 2013. http://www4.utsouthwestern.edu/breasthealth/cagene.
46. Cleveland Clinic. Risk calculator for estimating a patient's risk for PTEN mutation. 2012. Available at:. Accessed February 1, 2013. http://www.lerner.ccf.org/gmi/ccscore/index.php.
47. Parmigiani G., Chen S., Iversen E.S., et al. Validity of models for predicting BRCA1 and BRCA2 mutations. Ann Intern Med 2007, 147:441-450. [Summary for patients in Ann Intern Med 2007;147(7):I38; PMID: 17909202].
48. Euhus D.M., Smith K.C., Robinson L., et al. Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. J Natl Cancer Inst 2002, 94:844-851.
49. Flynn B.S., Wood M.E., Ashikaga T., et al. Primary care physicians' use of family history for cancer risk assessment. BMC Fam Pract 2010, 11:45.
50. Bellcross C. Further development and evaluation of a breast/ovarian cancer genetics referral screening tool. Genet Med 2010, 12:240.
51. Bellcross C.A., Lemke A.A., Pape L.S., et al. Evaluation of a breast/ovarian cancer genetics referral screening tool in a mammography population. Genet Med 2009, 11:783-789.
52. Kandel M.J., Stadler Z., Masciari S., et al. Prevalence of BRCA1 mutations in triple negative breast cancer. J Clin Oncol 2006, 24:5s. [abstract 508].
53. Ford D., Easton D.F., Stratton M., et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families: the breast cancer linkage consortium. Am J Hum Genet 1998, 62:676-689.
54. Antoniou A., Pharoah P.D., Narod S., et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003, 72:1117-1130.
55. King M.C., Marks J.H., Mandell J.B. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003, 302:643-646.
56. Panchal S., Bordeleau L., Poll A., et al. Does family history predict the age at onset of new breast cancers in BRCA1 and BRCA2 mutation-positive families?. Clin Genet 2010, 77:273-279.
57. Antoniou A.C., Pharoah P.D., Narod S., et al. Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J Med Genet 2005, 42:602-603.
58. Kotsopoulos J., Lubinski J., Lynch H.T., et al. Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Causes Control 2005, 16:667-674.
59. Gronwald J., Byrski T., Huzarski T., et al. Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland. Breast Cancer Res Treat 2006, 95:105-109.
60. Kotsopoulos J., Lubinski J., Lynch H.T., et al. Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 2007, 105:221-228.
61. Cullinane C.A., Lubinski J., Neuhausen S.L., et al. Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. Int J Cancer 2005, 117:988-991.
62. Jernstrom H., Lubinksi J., Lynch H.T., et al. Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2004, 96:209-214.
63. Eisen A., Lubinski J., Gronwald J., et al. Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst 2008, 100:1361-1367.
64. Nkondjock A., Ghadirian P., Kotsopoulos J., et al. Coffee consumption and breast cancer risk among BRCA1 and BRCA2 mutation carriers. Int J Cancer 2006, 118:103-107.
65. Nkondjock A., Robidoux A., Paredes Y., et al. Diet, lifestyle and BRCA-related breast cancer risk among French-Canadians. Breast Cancer Res Treat 2006, 98:285-294.
66. Gronwald J., Pijpe A., Byrski T., et al. Early radiation exposures and BRCA1-associated breast cancer in young women from Poland. Breast Cancer Res Treat 2008, 112:581-584.
67. Kriege M., Brekelmans C.T., Boetes C., et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004, 351:427-437.
68. Leach M.O., Boggis C.R., Dixon A.K., et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 2005, 365:1769-1778.
69. Warner E., Plewes D.B., Hill K.A., et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 2004, 292:1317-1325.
70. Sardanelli F., Podo F., D'Agnolo G., et al. Multicenter comparative multimodality surveillance of women at genetic-familial high risk for breast cancer (HIBCRIT study): interim results. Radiology 2007, 242:698-715.
71. Weinstein S.P., Localio A.R., Conant E.F., et al. Multimodality screening of high-risk women: a prospective cohort study. J Clin Oncol 2009, 27:6124-6128.
72. Hagen A.I., Kvistad K.A., Maehle L., et al. Sensitivity of MRI versus conventional screening in the diagnosis of BRCA-associated breast cancer in a national prospective series. Breast 2007, 16:367-374.
73. Kelly K., Dean J., Comulada W., et al. Breast cancer detection using automated whole breast ultrasound and mammography in radiographically dense breasts. Eur Radiol 2010, 20:734-742.
74. Saslow D., Boetes C., Burke W., et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2010, 57:75-89. [Erratum appears in CA Cancer J Clin 2007;57(3):185].
75. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998, 90:1371-1388.
76. King M.C., Wieand S., Hale K., et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 2001, 286:2251-2256.
77. James P.A., Doherty R., Harris M., et al. Optimal selection of individuals for BRCA mutation testing: a comparison of available methods. J Clin Oncol 2006, 24:707-715.
78. Lakhani S.R., Van De Vijver M.J., Jacquemier J., et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002, 20:2310-2318.
79. Robson M., Gilewski T., Haas B., et al. BRCA-associated breast cancer in young women. J Clin Oncol 1998, 16:1642-1649.
80. Metcalfe K.A., Birenbaum-Carmeli D., Lubinski J., et al. International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer 2008, 122:2017-2022.
81. Rebbeck T.R., Kauff N.D., Domchek S.M. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 2009, 101:80-87.
82. Finch A., Beiner M., Lubinski J., et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA 2006, 296:185-192.
83. Norquist B.M., Garcia R.L., Allison K.H., et al. The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations. Cancer 2010, 116:5261-5271.
84. Crum C.P., Drapkin R., Kindelberger D., et al. Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. Clin Med Res 2007, 5:35-44.
85. Powell C.B., Kenley E., Chen L.M., et al. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J Clin Oncol 2005, 23:127-132.
86. Colgan T.J., Murphy J., Cole D.E., et al. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol 2001, 25:1283-1289.
87. Rebbeck T.R., Lynch H.T., Neuhausen S.L., et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002, 346:1616-1622.
88. Kauff N.D., Barakat R.R. Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2. J Clin Oncol 2007, 25:2921-2927.
89. Key T.J., Appleby P.N., Reeves G.K., et al. Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. Br J Cancer 2011, 105:709-722.
90. Domchek S.M., Friebel T.M., Singer C.F., et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010, 304:967-975.
91. Kauff N.D., Domchek S.M., Friebel T.M., et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol 2008, 26:1331-1337.
92. Finch A., Metcalfe K.A., Chiang J.K., et al. The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation. Gynecol Oncol 2011, 121:163-168.
93. Rebbeck T.R., Friebel T., Wagner T., et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2005, 23:7804-7810.
94. Heemskerk-Gerritsen B.A., Brekelmans C.T., Menke-Pluymers M.B., et al. Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic. Ann Surg Oncol 2007, 14:3335-3344.
95. Meijers-Heijboer H., van Geel B., van Putten W.L., et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001, 345:159-164.
96. Hartmann L.C., Schaid D.J., Woods J.E., et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999, 340:77-84.
97. Brandberg Y., Sandelin K., Erikson S., et al. Psychological reactions, quality of life, and body image after bilateral prophylactic mastectomy in women at high risk for breast cancer: a prospective 1-year follow-up study. J Clin Oncol 2008, 26:3943-3949.
98. Rebbeck T.R., Friebel T., Lynch H.T., et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004, 22:1055-1062.
99. Hartmann L.C., Sellers T.A., Schaid D.J., et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 2001, 93:1633-1637.
100. Rusby J.E., Smith B.L., Gui G.P. Nipple-sparing mastectomy. Br J Surg 2010, 97:305-316.
101. Dreadin J., Sarode V., Saint-Cyr M., et al. Risk of residual breast tissue after skin-sparing mastectomy. Breast J 2012, 18:248-252.
102. Stolier A.J., Wang J. Terminal duct lobular units are scarce in the nipple: implications for prophylactic nipple-sparing mastectomy: terminal duct lobular units in the nipple. Ann Surg Oncol 2008, 15:438-442.
103. Tai Y.C., Domchek S., Parmigiani G., et al. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2007, 99:1811-1814.
104. Mohamad H.B., Apffelstaedt J.P. Counseling for male BRCA mutation carriers: a review. Breast 2008, 17:441-450.
105. Thorne H., Willems A.J., Niedermayr E., et al. Decreased prostate cancer-specific survival of men with BRCA2 mutations from multiple breast cancer families. Cancer Prev Res (Phila) 2011, 4:1002-1010.
106. Brachot-Simeonova I., Morin G., Gillaux C., et al. Bull Cancer 2012, 99:417-423. [inFrench].
107. Euhus D., Robinson L. Genetic counseling and genetic testing in the preoperative evaluation of breast cancer patients. Curr Breast Cancer Rep 2012, 4:102-109.
108. Liebens F.P., Carly B., Pastijn A., et al. Management of BRCA1/2 associated breast cancer: a systematic qualitative review of the state of knowledge in 2006. Eur J Cancer 2007, 43:238-257.
109. Pierce L.J., Phillips K.A., Griffith K.A., et al. Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. Breast Cancer Res Treat 2010, 121:389-398.
110. Lee E.H., Park S.K., Park B., et al. Effect of BRCA1/2 mutation on short-term and long-term breast cancer survival: a systematic review and meta-analysis. Breast Cancer Res Treat 2010, 122:11-25.
111. Goodwin P.J., Phillips K.A., West D.W., et al. Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an international prospective breast cancer family registry population-based cohort study. J Clin Oncol 2012, 30:19-26.
112. Garcia-Etienne C.A., Barile M., Gentilini O.D., et al. Breast-conserving surgery in BRCA1/2 mutation carriers: are we approaching an answer?. Ann Surg Oncol 2009, 16:3380-3387.
113. Haffty B.G., Harrold E., Khan A.J., et al. Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet 2002, 359:1471-1477.
114. Smith B.D., Arthur D.W., Buchholz T.A., et al. Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys 2009, 74:987-1001.
115. Metcalfe K., Gershman S., Lynch H.T., et al. Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer 2011, 104:1384-1392.
116. Bedrosian I., Hu C.Y., Chang G.J. Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients. J Natl Cancer Inst 2010, 102:401-409.
117. Boughey J.C., Hoskin T.L., Degnim A.C., et al. Contralateral prophylactic mastectomy is associated with a survival advantage in high-risk women with a personal history of breast cancer. Ann Surg Oncol 2010, 17:2702-2709.
118. Chappuis P.O., Goffin J., Wong N., et al. A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer. J Med Genet 2002, 39:608-610.
119. Delaloge S, Pautier P, Kloos I, et al. BRCA1-linked breast cancer (BC) is highly more chemosensitive than its BRCA2-linked or sporadic counterparts, 27th Congress of the European Society for Medical Oncology. Nice (France): October 18-22, 2002.
120. Hubert A., Mali B., Hamburger T., et al. Response to neo-adjuvant chemotherapy in BRCA1 and BRCA2 related stage III breast cancer. Fam Cancer 2009, 8:173-177.
121. Wysocki P.J., Korski K., Lamperska K., et al. Primary resistance to docetaxel-based chemotherapy in metastatic breast cancer patients correlates with a high frequency of BRCA1 mutations. Med Sci Monit 2008, 14:SC7-SC10.
122. Byrski T., Gronwald J., Huzarski T., et al. Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers. Breast Cancer Res Treat 2008, 108:289-296.
123. Stordal B., Pavlakis N., Davey R. A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship. Cancer Treat Rev 2007, 33:688-703.
124. Fedier A., Steiner R.A., Schwarz V.A., et al. The effect of loss of BRCA1 on the sensitivity to anticancer agents in p53-deficient cells. Int J Oncol 2003, 22:1169-1173.
125. Byrski T., Gronwald J., Huzarski T., et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 2010, 28:375-379.
126. Byrski T., Huzarski T., Dent R., et al. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat 2009, 115:359-363.
127. Fong P.C., Boss D.S., Yap T.A., et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009, 361:123-134.
128. Tutt A., Robson M., Garber J.E., et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010, 376:235-244.
129. Walsh T., Casadei S., Lee M.K., et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A 2011, 108:18032-18037.
130. Walsh T., Lee M.K., Casadei S., et al. Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc Natl Acad Sci U S A 2010, 107:12629-12633.
131. Ambry Genetics. BreastNext. 2012. Available at:. Accessed February 1, 2013. http://www.ambrygen.com/tests/breastnext.
132. National Comprehensive Cancer Network. Colorectal Cancer Screening, NCCN Clinical Practice Guidelines in Oncology v2.2012. Fort Washington (PA): 2012. Available at:. Accessed February 1, 2013. http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf.
133. Beggs A.D., Latchford A.R., Vasen H.F., et al. Peutz-Jeghers syndrome: a systematic review and recommendations for management. Gut 2010, 59:975-986.
134. Narod S.A. Testing for CHEK2 in the cancer genetics clinic: ready for prime time?. Clin Genet 2010, 78:1-7.
135. Ferner R.E., Huson S.M., Thomas N., et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet 2007, 44:81-88.
136. Niendorf K.B., Tsao H. Cutaneous melanoma: family screening and genetic testing. Dermatol Ther 2006, 19:1-8.
137. Kefford R.F., Newton Bishop J.A., Bergman W., et al. Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: a consensus statement of the melanoma genetics consortium. J Clin Oncol 1999, 17:3245-3251.
138. Lynch H.T., Fusaro R.M., Lynch J.F., et al. Pancreatic cancer and the FAMMM syndrome. Fam Cancer 2008, 7:103-112.